REGN vs RNXT · P/E 14, rev $14.34B vs rev $266.0K
Regeneron Pharmaceuticals Inc (REGN) versus RenovoRx Inc (RNXT) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
RenovoRx Inc (RNXT) is a biotechnology company listed on US.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported RNXT revenue for 2025-09-30 was $266.0K. Net income was -$2.9M. Revenue was down 37.0% from 2025-06-30 to 2025-09-30. RNXT currently screens at market cap $47.0M.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. RNXT currently screens at market cap $47.0M.
Not investment advice. Open the REGN and RNXT stock pages for the full models.
Not investment advice.